Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (17)

2023

  1. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

    Haematologica, Vol. 108, Núm. 1, pp. 110-121

2022

  1. A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper

    Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 968-980

2019

  1. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders

    AIDS, Vol. 33, Núm. 9, pp. 1441-1447

  2. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party

    Bone Marrow Transplantation, Vol. 54, Núm. 10, pp. 1625-1631

  3. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

    Cancer, Vol. 125, Núm. 1, pp. 90-98

2018

  1. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

    Blood Advances, Vol. 2, Núm. 14, pp. 1719-1737

  2. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party

    British Journal of Haematology, Vol. 181, Núm. 1, pp. 86-96

  3. Transplant results in adults with Fanconi anaemia

    British Journal of Haematology, Vol. 180, Núm. 1, pp. 100-109

2017

  1. Haploidentical transplant in patients with myelodysplastic syndrome

    Blood Advances, Vol. 1, Núm. 22, pp. 1876-1883

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  3. Single umbilical cord blood with or without CD341 cells from a third-party donor in adults with leukemia

    Blood Advances, Vol. 1, Núm. 15, pp. 1047-1055

2015

  1. The genotype of the donor for the (GT)n polymorphism in the promoter/enhancer of FOXP3 Is associated with the development of severe acute GVHD but does not affect the GVL effect after myeloablative HLA-Identical allogeneic stem cell transplantation

    PLoS ONE, Vol. 10, Núm. 10

2006

  1. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]

    Leukemia

2005

  1. Inolimomab in steroid-refratory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Retrospective analysis and comparison with other interleukin-2 receptor antibodies

    Transplantation, Vol. 80, Núm. 6, pp. 782-788

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

2002

  1. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant

    Bone Marrow Transplantation, Vol. 30, Núm. 2, pp. 63-68

1998

  1. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry

    Bone Marrow Transplantation, Vol. 21, Núm. 2, pp. 133-140